RE:RE:RE:What about promises before Covid?There have been some lessons the company has learned as well. They thought onboarding would have been simpler (and they had a number of issues with reimbursements). But, I don't imagine the new contracts, primarily with Medicare patients, will have the same issues -- outside of COVID.
I understand how the market is judging/valuing the company. Mistakes of the past have amplified the discount valuation. But, the technology is great, the management team has established a track record on the health care side, and the opportunity is massive.
At these levels, I don't even think the market is properly ascribing value to the pipeline alone. If they onboard at any decent rate from August and onwards...we're going to be laughing that this company was only worth 38 million...